Peptides of pineal gland and thymus prolong human life

This 2003 paper in *Neuroendocrinology Letters* is the English-language presentation of the same 266-elderly-participant 6–8 year clinical study originally published in 2002 in *Advances in Gerontology* (Russian: *Uspekhi Gerontologii*). The two papers cover the same dataset; the 2002 Russian paper is the primary publication, and this 2003 NEL paper is the international-readership version with the same authorship from the St. Petersburg Institute of Bioregulation and Gerontology and the Kiev Institute of Gerontology. The study design enrolled 266 elderly and older persons across three treatment arms — Thymalin alone, Epithalamin alone, and the Thymalin + Epithalamin combination — against an untreated control group, with bioregulators applied during the first 2–3 years of the 6–8 year observation window. One subgroup received the combination annually for the full six years. Outcomes were broad: cardiovascular, endocrine, immune, and nervous-system parameters; acute respiratory disease incidence; manifestations of ischemic heart disease, hypertension, osteoarthritis, and osteoporosis; and all-cause mortality. Key reported results: acute respiratory disease incidence dropped 2.0–2.4-fold in treated groups; mortality decreased 2.0–2.1-fold with Thymalin alone, 1.6–1.8-fold with Epithalamin alone, 2.5-fold with the combination delivered in the first 2–3 years, and 4.1-fold in the subgroup receiving the combination annually for the full six years — all referenced against the untreated controls. The investigators frame the mechanism as "homeostasis restoration" via peptide-mediated bioregulation across the endocrine + immune axes. This is the substrate from which the modern Khavinson-peptide commercial line (and the synthetic peptides Epitalon and Vilon, derived as the active fragments of these natural extracts) was developed. The 4.1-fold mortality reduction is the load-bearing claim that has shaped the entire Khavinson-peptide narrative for two decades.

The trial is non-randomized, non-blinded, and conducted by the institute that developed and now commercializes the Khavinson peptide line — both meaningful conflicts of interest in long-duration mortality studies where small differences in baseline characteristics can produce large differences in long-term outcomes. The methodological detail required to evaluate selection bias (matching procedure, control-arm refusal rate, attrition handling) is not visible in the publicly accessible abstract or summary; the underlying methodological transparency remains a credibility-limiting factor. The materials studied — Thymalin and Epithalamin — are polypeptide *fractions* extracted from animal tissues (calf thymus and calf pineal gland respectively), not the modern synthetic short peptides that the Khavinson group later isolated as the "active fragments" (Vilon = Lys-Glu for thymic activity; Epitalon = Ala-Glu-Asp-Gly for pineal activity). Translating the geroprotective evidence onto the synthetic peptides is a one-step inference that is mechanistically plausible but not directly demonstrated in the same long-duration human cohort. The paper has not been independently replicated outside the original Russian research group's network. The modern English-language literature on Epitalon and Vilon cites this paper but reports shorter-duration mechanistic studies (telomerase activation, gene expression) rather than independent long-duration mortality replications. The 4.1-fold mortality reduction headline has stood unreplicated for over two decades, which is itself information about the evidence depth. The 2002 *Advances in Gerontology* (Russian) and 2003 *Neuroendocrinology Letters* (English) papers should be read as a single dataset with two publication venues. Citing one without acknowledging the other risks double-counting the evidence depth of a single observational study.